Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer

Nature Clinical Practice Oncology volume 2, pages 296–297 (2005)Cite this article

boxed-textKobayashi S et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786–792

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pao W et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73

    Article  Google Scholar 

  2. Chen LL et al. (2004) A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64: 5913–5919

    Article  CAS  Google Scholar 

  3. Azam M et al. (2003) Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831–843

    Article  CAS  Google Scholar 

  4. Mitsudomi T et al. (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513–2520

    Article  CAS  Google Scholar 

  5. Han SW et al. (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493–2501

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Lisa Hutchinson, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Head of the Department of Medical Oncology of the Free University Medical Center, Amsterdam, The Netherlands

    Giuseppe Giaccone

Authors
  1. Giuseppe Giaccone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Giaccone.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Glossary

AUTODOCK 3.0

A suite of automated docking tools, designed to predict how small molecules bind to a receptor of known 3D structure. (DS Goodall and GM Morris, The Scripps Research Institute, CA, USA 1998)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giaccone, G. EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer. Nat Rev Clin Oncol 2, 296–297 (2005). https://doi.org/10.1038/ncponc0200

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0200

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing